Cargando…

Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study

BACKGROUND: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a worrisome aspect of the disease due to their high incidence in critically ill patients and their poor clinical outcomes. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and low mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fachri, Muhammad, Hatta, Mochammad, Tarigan, Sefia Nabila Nur Azmi, Akaputra, Risky, Dwiyanti, Ressy, Syukri, Ahmad, Junita, Ade Rifka, Primaguna, Muhammad Reza, Febrianty, Andini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238275/
https://www.ncbi.nlm.nih.gov/pubmed/35784948
http://dx.doi.org/10.1016/j.amsu.2022.104042
_version_ 1784737008851091456
author Fachri, Muhammad
Hatta, Mochammad
Tarigan, Sefia Nabila Nur Azmi
Akaputra, Risky
Dwiyanti, Ressy
Syukri, Ahmad
Junita, Ade Rifka
Primaguna, Muhammad Reza
Febrianty, Andini
author_facet Fachri, Muhammad
Hatta, Mochammad
Tarigan, Sefia Nabila Nur Azmi
Akaputra, Risky
Dwiyanti, Ressy
Syukri, Ahmad
Junita, Ade Rifka
Primaguna, Muhammad Reza
Febrianty, Andini
author_sort Fachri, Muhammad
collection PubMed
description BACKGROUND: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a worrisome aspect of the disease due to their high incidence in critically ill patients and their poor clinical outcomes. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) (fondaparinux) in hospitalized COVID-19 patients with hypercoagulable complications. MATERIAL AND METHODS: The study design used a retrospective cohort approach incorporating pre- and post-tests via secondary data extracted from the medical records of inpatients with confirmed COVID-19. RESULTS: Among the 98 individuals studied (52% women; 30.6% at >60 years of age), 35 patients received UFH, while the remaining 63 patients received LMWH (fondaparinux). The greatest decrease in the D-dimer value (0.01 ± 0.5 g fibrinogen equivalent units/mL) was observed in 12 (34.3%) and 15 (23.8%) patients in the UFH and LMWH (fondaparinux) groups, respectively. Most inpatients with confirmed COVID-19 were aged 50–59 years and were women. CONCLUSION: There was a tendency toward increased D-dimer, normal prothrombin time, normal activated partial thromboplastin clotting time, and increased fibrinogen values in each COVID-19 patient. The results demonstrated a significant relationship between the D-dimer and prothrombin time parameter in confirmed COVID-19 inpatients.
format Online
Article
Text
id pubmed-9238275
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92382752022-06-28 Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study Fachri, Muhammad Hatta, Mochammad Tarigan, Sefia Nabila Nur Azmi Akaputra, Risky Dwiyanti, Ressy Syukri, Ahmad Junita, Ade Rifka Primaguna, Muhammad Reza Febrianty, Andini Ann Med Surg (Lond) Cohort Study BACKGROUND: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a worrisome aspect of the disease due to their high incidence in critically ill patients and their poor clinical outcomes. The aim of this study was to compare the effectiveness of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) (fondaparinux) in hospitalized COVID-19 patients with hypercoagulable complications. MATERIAL AND METHODS: The study design used a retrospective cohort approach incorporating pre- and post-tests via secondary data extracted from the medical records of inpatients with confirmed COVID-19. RESULTS: Among the 98 individuals studied (52% women; 30.6% at >60 years of age), 35 patients received UFH, while the remaining 63 patients received LMWH (fondaparinux). The greatest decrease in the D-dimer value (0.01 ± 0.5 g fibrinogen equivalent units/mL) was observed in 12 (34.3%) and 15 (23.8%) patients in the UFH and LMWH (fondaparinux) groups, respectively. Most inpatients with confirmed COVID-19 were aged 50–59 years and were women. CONCLUSION: There was a tendency toward increased D-dimer, normal prothrombin time, normal activated partial thromboplastin clotting time, and increased fibrinogen values in each COVID-19 patient. The results demonstrated a significant relationship between the D-dimer and prothrombin time parameter in confirmed COVID-19 inpatients. Elsevier 2022-06-28 /pmc/articles/PMC9238275/ /pubmed/35784948 http://dx.doi.org/10.1016/j.amsu.2022.104042 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Cohort Study
Fachri, Muhammad
Hatta, Mochammad
Tarigan, Sefia Nabila Nur Azmi
Akaputra, Risky
Dwiyanti, Ressy
Syukri, Ahmad
Junita, Ade Rifka
Primaguna, Muhammad Reza
Febrianty, Andini
Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study
title Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study
title_full Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study
title_fullStr Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study
title_full_unstemmed Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study
title_short Heparin for patients with coronavirus disease 2019 and hypercoagulation complications: A cohort study
title_sort heparin for patients with coronavirus disease 2019 and hypercoagulation complications: a cohort study
topic Cohort Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238275/
https://www.ncbi.nlm.nih.gov/pubmed/35784948
http://dx.doi.org/10.1016/j.amsu.2022.104042
work_keys_str_mv AT fachrimuhammad heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT hattamochammad heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT tarigansefianabilanurazmi heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT akaputrarisky heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT dwiyantiressy heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT syukriahmad heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT junitaaderifka heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT primagunamuhammadreza heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy
AT febriantyandini heparinforpatientswithcoronavirusdisease2019andhypercoagulationcomplicationsacohortstudy